Ribavirin enhances IFN-α signalling and MxA expression: A novel immune modulation mechanism during treatment of HCV

44Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

The nucleoside analogue Ribavirin significantly increases patient response to IFN-α treatment of HCV, by directly inhibiting viral replication. Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific interferon sensitive gene (ISG) expression by amplifying the IFN-α-JAK/STAT pathway. We found that IFN-α-induced STAT1 and STAT3 phosphorylation was increased in hepatocytes co-treated with Ribavirin and IFN-α, compared to IFN-α alone. Ribavirin specifically enhanced IFN-α induced mRNA and protein of the anti-viral mediator MxA, which co-localised with HCV core protein. These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation, also enhances IFN-α-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may enhance IFN-α anti-viral activity against HCV. © 2011 Stevenson et al.

Cite

CITATION STYLE

APA

Stevenson, N. J., Murphy, A. G., Bourke, N. M., Keogh, C. A., Hegarty, J. E., & O’Farrelly, C. (2011). Ribavirin enhances IFN-α signalling and MxA expression: A novel immune modulation mechanism during treatment of HCV. PLoS ONE, 6(11). https://doi.org/10.1371/journal.pone.0027866

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free